We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Antigagging Effect of Granisetron (Kytril), an Antiemetic Drug, in Dental Situations

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2007 by Hadassah Medical Organization.
Recruitment status was:  Not yet recruiting
ClinicalTrials.gov Identifier:
First Posted: July 17, 2007
Last Update Posted: November 30, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hadassah Medical Organization

Antigagging effect of kytril (granisetron) an antiemetic drug in dental situations

Gagging in dental situations can be a problem to the patient and the operating dentist. There are not proven methods of eliminating this reflex which sometimes will not allow routine quality dental care.

Pharmacological and behavioral approaches to eliminate this reflex have been tried with limited success.

This suggested study will test a potent antiemetic drug used in other clinical situations such as antineoplastic treatment. Granisetron is a potential antagonist for the 5-hydroxytryptamine3-receptor - 5HT(3), The drug binds to the receptor and blocks the effect of nausea and vomiting. Kytril mechanism of action was successfully proven for various medical situations as a potential antiemetic agent. Our Center for dental sedation and anesthesia in the oral medicine department have received approval to use Granisetron as an antigagging drug in dental situations based on several pilot studies conducted in other medical centers in different clinical situations such as strabismus corrections, post hysterectomy and others. Our preliminary clinical impression is that pre-emptive IV administration of this drug to patients with increased gag reflex is beneficial.

In our research we try to investigate the possibility of using kytril in dental situations.

In the first stage of this research we will study the INTRAVENOUS use of this drug and its effects On normal subjects compare them to themselves with placebo. According to the results of this study we will go on to the second stage of the research and try the same drug under oral administration.

The purpose of this study is to test the antigagging effect of this drug in a controlled manner in dental situations.

Our working hypothesis is that administration of this drug in dental situations with success, will allow many patients to receive good dental care

Condition Intervention
Antiggaging Effect Antiemetic Granisetron Gag Reflex Dental Situations Drug: GRANISETRON

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Masking: Double

Resource links provided by NLM:

Further study details as provided by Hadassah Medical Organization:


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • normal subjects

Exclusion Criteria:

  • presence of systemic disease
  • subjects under medication or drug or food complementary agents
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00502437

Contact: Eliezer Kaufman, Professor +972.2.6776121 ekaufman@cc.huji.ac.il
Contact: Silvina Friedlander-Barenboim, DMD +972.2.6776157 silvina@hadassah.org.il

Hadassah Medical Organization Not yet recruiting
Jerusalem, Israel
Contact: Arik Tzukert, DMD    00 972 2 6776095    arik@hadassah.org.il   
Contact: Hadas Lemberg, PhD    00 972 2 6777572    lhadas@hadassah.org.il   
Principal Investigator: Eliezer Kaufman, DMD         
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Eliezer Kaufman, DMD Hadassah Medical Organization
  More Information

ClinicalTrials.gov Identifier: NCT00502437     History of Changes
Other Study ID Numbers: 376-11.05.07HMO-CTIL
First Submitted: July 16, 2007
First Posted: July 17, 2007
Last Update Posted: November 30, 2010
Last Verified: June 2007

Additional relevant MeSH terms:
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action